Cargando…

The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ

OBJECTIVE: Several studies have shown that anticoagulation can improve survival outcomes in patients with sepsis-associated disseminated intravascular coagulation (DIC). A guideline from Japan in 2020 suggested two therapeutic agents for sepsis-associated DIC treatment: antithrombin (AT) replacement...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Makoto, Ehama, Yoshimatsu, Hirayama, Suguru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000919/
https://www.ncbi.nlm.nih.gov/pubmed/35418787
http://dx.doi.org/10.2147/OAEM.S359216
_version_ 1784685554653200384
author Kobayashi, Makoto
Ehama, Yoshimatsu
Hirayama, Suguru
author_facet Kobayashi, Makoto
Ehama, Yoshimatsu
Hirayama, Suguru
author_sort Kobayashi, Makoto
collection PubMed
description OBJECTIVE: Several studies have shown that anticoagulation can improve survival outcomes in patients with sepsis-associated disseminated intravascular coagulation (DIC). A guideline from Japan in 2020 suggested two therapeutic agents for sepsis-associated DIC treatment: antithrombin (AT) replacement therapy and recombinant thrombomodulin (rTM) preparation. In 2021, our preliminary study proposed that different organs of septic infection might lead to distinct treatment outcomes following different therapies against DIC. In this study, we created a subanalysis on the influence of AT replacement therapy and rTM preparations on overall survival (OS) by comparing two causative organs: biliary and respiratory tract infections. PATIENTS AND METHODS: This retrospective cohort study in a single institution involved patients with sepsis-associated DIC treated by either AT or rTM who were categorized based on sources of infection. The two groups defined for this study were biliary (n = 62) and respiratory tract infection (n = 84). To assess the clinical efficacy of AT and rTM, 30-day OS was examined using a stepwise variable selection for a Cox proportional hazards model. RESULTS: The analysis of factors influencing OS by each group showed that rTM preparation remained a significant factor in the biliary tract infection group (HR 0.306, 95% CI 0.133–0.706). In the respiratory tract infection group, the score of the Acute Physiology and Chronic Health Evaluation II (HR 1.109, 95% CI 1.051–1.170), polymyxin B hemoperfusion (HR 0.390, 95% CI 0.161–0.944), and AT replacement therapy (HR 0.510, 95% CI 0.261–0.997) were established as significant factors. CONCLUSION: This study revealed that the OS of patients with biliary tract and respiratory tract infections differed depending on the DIC therapeutic agent. Based on these results, we could suggest that it is necessary to develop individualized treatment strategies for septic infections, taking into consideration the differences in the infected organs.
format Online
Article
Text
id pubmed-9000919
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90009192022-04-12 The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ Kobayashi, Makoto Ehama, Yoshimatsu Hirayama, Suguru Open Access Emerg Med Original Research OBJECTIVE: Several studies have shown that anticoagulation can improve survival outcomes in patients with sepsis-associated disseminated intravascular coagulation (DIC). A guideline from Japan in 2020 suggested two therapeutic agents for sepsis-associated DIC treatment: antithrombin (AT) replacement therapy and recombinant thrombomodulin (rTM) preparation. In 2021, our preliminary study proposed that different organs of septic infection might lead to distinct treatment outcomes following different therapies against DIC. In this study, we created a subanalysis on the influence of AT replacement therapy and rTM preparations on overall survival (OS) by comparing two causative organs: biliary and respiratory tract infections. PATIENTS AND METHODS: This retrospective cohort study in a single institution involved patients with sepsis-associated DIC treated by either AT or rTM who were categorized based on sources of infection. The two groups defined for this study were biliary (n = 62) and respiratory tract infection (n = 84). To assess the clinical efficacy of AT and rTM, 30-day OS was examined using a stepwise variable selection for a Cox proportional hazards model. RESULTS: The analysis of factors influencing OS by each group showed that rTM preparation remained a significant factor in the biliary tract infection group (HR 0.306, 95% CI 0.133–0.706). In the respiratory tract infection group, the score of the Acute Physiology and Chronic Health Evaluation II (HR 1.109, 95% CI 1.051–1.170), polymyxin B hemoperfusion (HR 0.390, 95% CI 0.161–0.944), and AT replacement therapy (HR 0.510, 95% CI 0.261–0.997) were established as significant factors. CONCLUSION: This study revealed that the OS of patients with biliary tract and respiratory tract infections differed depending on the DIC therapeutic agent. Based on these results, we could suggest that it is necessary to develop individualized treatment strategies for septic infections, taking into consideration the differences in the infected organs. Dove 2022-04-07 /pmc/articles/PMC9000919/ /pubmed/35418787 http://dx.doi.org/10.2147/OAEM.S359216 Text en © 2022 Kobayashi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Kobayashi, Makoto
Ehama, Yoshimatsu
Hirayama, Suguru
The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title_full The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title_fullStr The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title_full_unstemmed The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title_short The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ
title_sort necessity of individualized treatment for sepsis-associated disseminated intravascular coagulation by infected organ
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000919/
https://www.ncbi.nlm.nih.gov/pubmed/35418787
http://dx.doi.org/10.2147/OAEM.S359216
work_keys_str_mv AT kobayashimakoto thenecessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan
AT ehamayoshimatsu thenecessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan
AT hirayamasuguru thenecessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan
AT kobayashimakoto necessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan
AT ehamayoshimatsu necessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan
AT hirayamasuguru necessityofindividualizedtreatmentforsepsisassociateddisseminatedintravascularcoagulationbyinfectedorgan